Fondaparinux Sodium (Arixtra®) for the treatment of ST segment elevation myocardial infarction (STEMI)

All Wales Medicines Strategy Group (AWMSG)

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
All Wales Medicines Strategy Group (AWMSG). Fondaparinux Sodium (Arixtra®) for the treatment of ST segment elevation myocardial infarction (STEMI) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 0508. 2008

Authors' conclusions
Fondaparinux (Arixtra®) should be recommended as an option for use in the treatment of ST segment elevation myocardial infarction (STEMI) in patients who are managed with thrombolytics or who are initially to receive no other form of reperfusion therapy. Treatment with fondaparinux (Arixtra®) and its monitoring/supervision should be retained under secondary care. AWMSG is of the opinion that fondaparinux (Arixtra®) would not be suitable for shared care within NHS Wales.

Final publication URL

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Anticoagulants; Polysaccharides; Myocardial Infarction

Language Published
English

Country of organisation
Wales

English summary
An English language summary is available.

Address for correspondence
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX Email: AWTTC@wales.nhs.uk

AccessionNumber
32012000447

Date abstract record published
08/08/2012